BPI 2026 · Biotech

Ultragenyx at BPI 2026

Novato, California

Ultragenyx brings 3 presentations to BPI 2026 in Boston. Its sessions focus on AAV gene therapy manufacturing and the route to approval. One sets out a cell bank characterization and qualification strategy for AAV producer cell lines.

OrganizationBPI 2026 Attendance
Ultragenyx
Novato, California
1 Associate Director · 1 SVP, Global CMC Development · 1 MSAT Executive Director
ultragenyx.com
Biotech
Develops and commercializes therapies for rare and ultra-rare genetic diseases, including AAV gene therapies.
Talk
Thu Sep 24
12:00pm–12:30pm
Cell Bank Characterization and Qualification Strategy for AAV PCLs
Gene Therapy Manufacturing & Analytics
Talk
Thu Sep 24
4:30pm–5:30pm
Panel Discussion: Starting with the End in Mind: Designing Smart and Phase Appropriate Manufacturing for Successful Cell and Gene Therapy Development
Development of Emerging Cell & Gene Therapies · with Mill Creek Consulting, Astellas Institute for Regenerative Medicine, Genetix Biotherapeutics
Panel
Fri Sep 25
9:00am–10:00am
Keynote Panel Discussion: Navigating BLA Success - Strategies for Streamlined Gene Therapy Approval Success
Gene Therapy Manufacturing & Analytics · with University College Cork, GenSight Biologics, Rocket Pharmaceuticals +1 more

Explore the full BPI 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full BPI 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Ultragenyx

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Informa Connect or the BioProcess International Conference & Exhibition. Submit a correction